Brain Cancer

Adjuvant Neratinib Does Not Improve Overall Survival in Glioblastoma, Yet May Offer Benefit for EGFR+ Subset

March 10, 2022

Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.

AV-GBM-1 Vaccine Improves Glioblastoma Outcomes

November 18, 2020

AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival (PFS) in patients with newly diagnosed glioblastoma, according to data from a phase 2 trial (NCT03400917).